BioCentury
ARTICLE | Finance

Ebb & Flow

July 30, 2007 7:00 AM UTC

Pharmion (PHRM) had its second bad week in a row, weighed down by the unanimous recommendation of FDA's Oncologic Drugs Advisory Committee last Tuesday against accelerated approval of Orplatna satraplatin from GPC Biotech (FSE:GPC; GPCB).

PHRM slid $0.97 to $24.42 on the week, after losing $1.76 to $25.39 the prior Friday when the ODAC briefing documents suggested the agency would delay action on Orplatna until overall survival data become available (see Cover Story). ...